Showing results (31-40 of 76) with videos related to

Sort By:
Pageof 8
Cancers|January 11, 2025
Machine Learning and Computed Tomography Radiomics to Predict Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer: A Pilot StudyIan Janzen, Cheryl Ho, Barbara Melosky, et al.
The Oncologist|May 30, 2019
Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung CancerBarbara Melosky, Rosalyn Juergens, Vera Hirsh, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie|May 11, 2020
Reducing time from colon cancer surgery to initiation of adjuvant chemotherapy: pilot projectBarbara Melosky, Renata D'Alpino Peixoto, Ahmer A Karimuddin, et al.
Molecular Diagnosis & Therapy|November 23, 2021
Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-AnalysisBarbara Melosky, Kato Kambartel, Maik Häntschel, et al.
Current Oncology (Toronto, Ont.)|January 20, 2023
Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort StudyRoy Avraham Hilzenrat, Stephen Yip, Barbara Melosky, et al.
Lung Cancer (Amsterdam, Netherlands)|March 21, 2023
Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendationsAlexander Sun, Bassam Abdulkarim, Normand Blais, et al.
Lung Cancer (Amsterdam, Netherlands)|August 18, 2019
PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancerGang Wang, Diana N Ionescu, Cheng-Han Lee, et al.
BMJ Open Quality|February 19, 2025
Reduced wait times for molecular-biomarker testing among patients with advanced lung cancer using parallel sample processing and closed-loop communication: the Continuous Oncopanel and ALK Status Tracking (COAST) ProjectSarah Yeo, Jane Sun, Kelly Zibrik, et al.
Current Oncology (Toronto, Ont.)|November 26, 2024
Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Recommendations Based on a Modified Delphi ProcessAnthony M Brade, Houda Bahig, Andrea Bezjak, et al.
Lung Cancer (Amsterdam, Netherlands)|November 7, 2013
A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced diseaseCaroline Mariano, Ian Bosdet, Aly Karsan, et al.
Pageof 8